Perspective Therapeutics, Inc. (NYSE:CATX – Free Report) – Equities research analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for Perspective Therapeutics in a research report issued on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings per share of ($0.90) for the year, up from their prior estimate of ($0.95). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.86) per share.
Perspective Therapeutics (NYSE:CATX – Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). The firm had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%.
Check Out Our Latest Analysis on CATX
Perspective Therapeutics Price Performance
NYSE CATX opened at $6.78 on Monday. Perspective Therapeutics has a 52-week low of $2.28 and a 52-week high of $19.05. The stock’s 50-day moving average is $12.37.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in CATX. Bleakley Financial Group LLC purchased a new stake in Perspective Therapeutics in the first quarter valued at approximately $40,000. nVerses Capital LLC purchased a new stake in shares of Perspective Therapeutics during the 3rd quarter valued at $57,000. US Bancorp DE raised its position in shares of Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after buying an additional 3,866 shares in the last quarter. Victory Capital Management Inc. bought a new stake in Perspective Therapeutics in the 2nd quarter worth approximately $117,000. Finally, Point72 DIFC Ltd bought a new stake in shares of Perspective Therapeutics in the 2nd quarter worth approximately $118,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.
Perspective Therapeutics Company Profile
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Featured Stories
- Five stocks we like better than Perspective Therapeutics
- Conference Calls and Individual Investors
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- Using the MarketBeat Dividend Tax Calculator
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- Consumer Discretionary Stocks Explained
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.